Distinguished in Multiple Myeloma

Weijun J. Fu

415 Fengyang Rd, 
Shanghai, CN 
Distinguished in Multiple Myeloma
415 Fengyang Rd, 
Shanghai, CN 
OverviewLocationsClinical Research

Overview

Weijun Fu practices in Shanghai, China. Fu is rated as a Distinguished expert by MediFind in the treatment of Multiple Myeloma. Their top areas of expertise are Multiple Myeloma, POEMS Syndrome, Rosai-Dorfman Disease, Non-Hodgkin Lymphoma, and Bone Marrow Transplant.

Their clinical research consists of co-authoring 69 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 50 articles and participated in 4 clinical trials in the study of Multiple Myeloma.

Locations

415 Fengyang Rd, Shanghai, 200003, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

China Continuation: A Single-Arm, Open-Label Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation
China Continuation: A Single-Arm, Open-Label Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation
Enrollment Status: Completed
Publish Date: March 21, 2025
Intervention Type: Drug
Study Drug: Ixazomib
Study Phase: Phase 3
A Phase III Randomized, Controlled, Multicenter, Open-label Study of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
A Phase III Randomized, Controlled, Multicenter, Open-label Study of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Enrollment Status: Active_not_recruiting
Publish Date: February 11, 2025
Intervention Type: Combination product
Study Drugs: Selinexor+Bortezomib+Dexamethasone, Bortezomib+Dexamethasone
Study Phase: Phase 3
An Open-Label, Single-Arm Study of ATG-010 Plus Dexamethasone in Patients With Multiple Myeloma Refractory to Prior Treatment With Immunomodulatory Agents and Proteasome Inhibitor
An Open-Label, Single-Arm Study of ATG-010 Plus Dexamethasone in Patients With Multiple Myeloma Refractory to Prior Treatment With Immunomodulatory Agents and Proteasome Inhibitor
Enrollment Status: Completed
Publish Date: June 15, 2023
Intervention Type: Drug
Study Drug: ATG-010
Study Phase: Phase 2
Frontline Therapy of GC012F Injection in Transplant Eligible Newly Diagnosed Multiple Myeloma Patients With High-Risk Profile
Frontline Therapy of GC012F Injection in Transplant Eligible Newly Diagnosed Multiple Myeloma Patients With High-Risk Profile
Enrollment Status: Unknown
Publish Date: August 03, 2022
Intervention Type: Biological
Study Drug: GC012F Injection
Study Phase: Phase 1/Phase 2
View 3 Less Clinical Trials

69 Total Publications

Development and validation of a prognostic staging system for primary plasma cell leukemia.
Development and validation of a prognostic staging system for primary plasma cell leukemia.
Journal: Journal of hematology & oncology
Published: April 30, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Fu's expertise for a condition
ConditionClose
      View All 18 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile